MY195821A - Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers - Google Patents

Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers

Info

Publication number
MY195821A
MY195821A MYPI2019004578A MYPI2019004578A MY195821A MY 195821 A MY195821 A MY 195821A MY PI2019004578 A MYPI2019004578 A MY PI2019004578A MY PI2019004578 A MYPI2019004578 A MY PI2019004578A MY 195821 A MY195821 A MY 195821A
Authority
MY
Malaysia
Prior art keywords
peptides
cells
tumor
present
relates
Prior art date
Application number
MYPI2019004578A
Inventor
Jens Fritsche
Sarah Kutscher
Andrea Mahr
Phillip Muller
Toni Weinschenk
Anita Wiebe
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Priority to MYPI2019004578A priority Critical patent/MY195821A/en
Publication of MY195821A publication Critical patent/MY195821A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor- associated T-cell peptide epitopes, alone or in combination with other tumor- associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically / immunologically active compounds and cells.
MYPI2019004578A 2019-08-08 2019-08-08 Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers MY195821A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI2019004578A MY195821A (en) 2019-08-08 2019-08-08 Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2019004578A MY195821A (en) 2019-08-08 2019-08-08 Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers

Publications (1)

Publication Number Publication Date
MY195821A true MY195821A (en) 2023-02-22

Family

ID=87569450

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019004578A MY195821A (en) 2019-08-08 2019-08-08 Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers

Country Status (1)

Country Link
MY (1) MY195821A (en)

Similar Documents

Publication Publication Date Title
PH12017500484A1 (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
PH12021550205A1 (en) Immunotherapy with b*07 restricted peptides and combination of peptides against cancers and related methods
PH12019502308A1 (en) Peptides and combination thereof for use in the immunotherapy against cancers
PH12021550346A1 (en) B*44 restricted peptides for use in immunotherapy against cancers and related methods
PH12020500051A1 (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
PH12021550581A1 (en) Immunotherapy with a*01 restricted peptides and combination of peptides against cancers and related methods
PH12020552013A1 (en) A*03 restricted peptides for use in immunotherapy against cancers and related methods
PH12020551958A1 (en) Peptides for use in immunotherapy against cancers
CR20210329A (en) Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods
MX2020005188A (en) Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers.
MY195821A (en) Novel Peptides and Combination of Peptides for use in Immunotherapy Against Hepatocellular Carcinoma (Hcc) and other Cancers
MY197679A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
MY197301A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
MY197794A (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
CR20200477A (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors